A new approach
to treating neuroinflammation
Small molecule therapies to treat central nervous system (CNS) diseases
To date, most recent drug development for CNS diseases has focused on removal of the proteins (beta amyloid, tau and alpha synuclein) that accumulate over the course of the disease. We are taking a different approach
There is an emerging consensus that neuroinflammation is a significant factor in CNS diseases, creating a therapeutic opportunity. NeuroTherapia is developing oral, small molecule therapeutics that inhibit microglia cells, which are known to express proteins that drive inflammation in the CNS. We believe our therapies offer a novel approach that could work well in combination with currently approved antibody therapies.
Our Lead Program: NTRX-07
NTRX-07 is an orally available small molecule that reduces inflammation and improves the brain's ability to form new connections, leading to improved learning and memory. This approach represents a new approach for the treatment of CNS conditions.
NeuroTherapia has completed Phase I and Phase 2a clinical studies in healthy volunteers and AD patients, which demonstrated the safety of NTRX-07 at doses predicted to be efficacious. The recently completed Phase 2a study met its core objectives and produced a consistent multi-domain signal across safety, PK, biomarkers, MRI, EEG and clinical outcomes that supports confidence in the further development of NTRX-07.